Condition

Transfusional Hemosiderosis (2)

Transfusional Iron Overload (2)

Beta-thalassemia (1)

Iron Chelation (1)

Iron Metabolism Disorders (1)

Iron Overload (1)

Metabolic Diseases (1)

Overall Status

Completed (1)

Withdrawn (1)

Sign in for free

Phase

phase 2 (2)

Sponsor

Novartis Pharmaceuticals (1)

Shire (1)

Collaborator

Intervention

deferasirox (2)

core study: deferasirox (1)

core study: deferoxamine (1)

deferoxamine (1)

extension: deferasirox to deferoxamine (1)

extension: deferoxamine to deferasirox (1)

spd602 (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (2)

Study Type

Interventional (2)

transfusional hemosiderosis

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Transfusional Iron Overload, Iron Overload, Iron Chelation Trial (SPD602, Deferasirox)

Withdrawn

Transfusional Iron Overload
+6 more

(no location specified)

Jun 1, 2021

Transfusional Iron Overload, Transfusional Hemosiderosis Trial in Worldwide (Core Study: Deferasirox, Core Study: Deferoxamine,

Completed

Has Results

Transfusional Iron Overload
Transfusional Hemosiderosis

Core Study: Deferasirox
+5 more

Toronto, Ontario, Canada
+20 more

Aug 13, 2014